0
POPSEpix Soars 50% On Alzheimer's Data These are promising results, but investors should be cautious: The Alzheimer's field is littered with failed attempts at developing a treatment. Late-stage results often don't match the promise seen in mid-stage trials. Still, this is better than the approved drugs in this field can do, and a reason to watch Epix.
3
Pops
Newest Clips
Latest Comments
Most Pops
Print
Save
Turn on live update